Chen Tai C, Holick Michael F
Vitamin D, Skin and Bone Research Laboratory, Section of Endocrinology, Diabetes and Nutrition, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Trends Endocrinol Metab. 2003 Nov;14(9):423-30. doi: 10.1016/j.tem.2003.09.004.
Human prostate cells contain receptors for 1alpha,25-dihydroxyvitamin D, the active form of vitamin D. Prostate cancer cells respond to vitamin D(3) with increases in differentiation and apoptosis, and decreases in proliferation, invasiveness and metastasis. These findings strongly support the use of vitamin D-based therapies for prostate cancer and/or as a second-line therapy if androgen deprivation fails. The association between either decreased sun exposure or vitamin D deficiency and the increased risk of prostate cancer at an earlier age, and with a more aggressive progression, indicates that adequate vitamin D nutrition should be a priority for men of all ages. Here we summarize recent advances in epidemiological and biochemical studies of the endocrine and autocrine systems associated with vitamin D and their implications for prostate cancer and in the evaluation of vitamin D(3) and its analogs in preventing and/or treating prostate cancer.
人类前列腺细胞含有1α,25 - 二羟基维生素D（维生素D的活性形式）的受体。前列腺癌细胞对维生素D3有反应，表现为分化增加、凋亡增加，增殖、侵袭和转移减少。这些发现有力地支持了基于维生素D的疗法用于前列腺癌治疗，以及在雄激素剥夺治疗失败时作为二线治疗。阳光照射减少或维生素D缺乏与前列腺癌在较年轻时发病风险增加以及病情进展更具侵袭性之间的关联，表明充足的维生素D营养应是所有年龄段男性的首要任务。在此，我们总结了与维生素D相关的内分泌和自分泌系统的流行病学及生化研究的最新进展，及其对前列腺癌的影响，以及维生素D3及其类似物在预防和/或治疗前列腺癌方面的评估情况。
